Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
18.56
+1.57 (9.24%)
At close: Jun 26, 2026, 4:00 PM EDT
18.06
-0.50 (-2.69%)
After-hours: Jun 26, 2026, 5:26 PM EDT

Crescent Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6173272515216575
Market Cap Growth
-1188.57%-83.31%-7.77%118.72%-59.13%
Enterprise Value
429.11119.2832.08110.92117.81-13.92
Last Close Price
18.5611.8624.90236.00303.00144.00
PS Ratio
51.9030.14-15196.902196.8664.95
PB Ratio
3.4381.1425363.20---
P/TBV Ratio
81.7530.6616054.88---
EV/Sales Ratio
36.1111.00-11091.801570.83-12.00
EV/EBITDA Ratio
-----0.22
EV/EBIT Ratio
-----0.22
EV/FCF Ratio
-----0.24
Debt / Equity Ratio
0.010.01-2.42000
Net Debt / Equity Ratio
-46.58-52.522716.00---
Net Debt / EBITDA Ratio
1.151.39-0.071.051.001.41
Net Debt / FCF Ratio
2.462.92-0.431.181.011.55
Asset Turnover
-0.0800.000.000.01
Quick Ratio
13.336.413.626.115.397.63
Current Ratio
13.786.563.626.415.717.68
Return on Equity (ROE)
-85.57%-167.78%-330.33%-90.78%-75.05%-60.49%
Return on Assets (ROA)
-74.25%-110.64%-98.94%-80.87%-64.87%-53.50%
Return on Invested Capital (ROIC)
-1286.26%-2164.53%-2549.22%-1834.55%-1442.19%-1266.82%
Return on Capital Employed (ROCE)
-83.84%-132.59%-124.18%-96.49%-75.57%-59.60%
Buyback Yield / Dilution
--1515.08%-1.79%-20.58%-2.10%-12.54%
Total Shareholder Return
--1515.08%-1.79%-20.58%-2.10%-12.54%
SEC Filings: 10-K · 10-Q